Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | PNMT | P11086 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6900583 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2TSHRCYP4F2CYP4A11HPGD | |
| SCHEMBL1903863 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2TSHRCYP4F2CYP4A11HPGD | |
| SCHEMBL18455288 | 0.86 | PNMT (0.40) | SMN1; SMN2TSHRCYP4F2CYP4A11HPGD | |
| SCHEMBL6901178 | 0.84 | EPHX2 (0.54) | SMN1; SMN2TSHRCYP4F2CYP4A11HPGD | |
| SCHEMBL1906000 | 0.84 | EPHX2 (0.54) | SMN1; SMN2TSHRCYP4F2CYP4A11HPGD | |
| SCHEMBL1930974 | 0.84 | EPHX2 (0.41) | SMN1; SMN2CYP4F2CYP4A11HPGDKDM4E | |
| SCHEMBL6901708 | 0.84 | EPHX2 (0.41) | SMN1; SMN2CYP4F2CYP4A11HPGDKDM4E | |
| SCHEMBL1931788 | 0.84 | EPHX2 (0.41) | SMN1; SMN2CYP4F2CYP4A11HPGDKDM4E | |
| SCHEMBL1903633 | 0.84 | EPHX2 (0.54) | SMN1; SMN2TSHRCYP4F2CYP4A11HPGD | |
| SCHEMBL15709525 | 0.83 | KDM4E (0.49) | SMN1; SMN2HPGDKDM4EMAPK1PNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2852573-B1 | N-[3-(2-CARBOXYETHYL)PHENYL]-PIPERIDIN-1-YL ACETAMIDE DERIVATIVES AND THEIR USE AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | Bayer Pharma AG (DE) | 2017-02-01 | — | — | EP | disclosed |
| EP-2852573-B1 | N-[3-(2-CARBOXYETHYL)PHENYL]-PIPERIDIN-1-YL ACETAMIDE DERIVATIVES AND THEIR USE AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | Bayer Pharma AG (DE) | 2017-02-01 | — | — | EP | disclosed |
| US-9309198-B2 | N-[3-(2-carboxyethyl)phenyl]piperidin-1-ylacetamide derivatives and use thereof as activators of soluble guanylate cyclase | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-04-12 | — | — | US | disclosed |
| US-9309198-B2 | N-[3-(2-carboxyethyl)phenyl]piperidin-1-ylacetamide derivatives and use thereof as activators of soluble guanylate cyclase | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-04-12 | — | — | US | disclosed |
| US-20150152050-A1 | N-[3-(2-CARBOXYETHYL)PHENYL]PIPERIDIN-1-YLACETAMIDE DERIVATIVES AND USE THEREOF AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-04 | — | — | US | disclosed |
| US-20150152050-A1 | N-[3-(2-CARBOXYETHYL)PHENYL]PIPERIDIN-1-YLACETAMIDE DERIVATIVES AND USE THEREOF AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-04 | — | — | US | disclosed |
| US-9018414-B2 | Substituted 3-phenylpropionic acids and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-28 | — | — | US | disclosed |
| US-9018414-B2 | Substituted 3-phenylpropionic acids and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-28 | — | — | US | disclosed |
| EP-2852573-A1 | N-[3-(2-CARBOXYETHYL)PHENYL]PIPERIDIN-1-YLACETAMIDE DERIVATIVES AND USE THEREOF AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | Bayer Pharma Aktiengesellschaft (DE) | 2015-04-01 | — | — | EP | disclosed |
| CN-104470895-A | N-[3-(2-carboxyethyl)phenyl]piperidin-1-ylacetamide derivatives and use thereof as activators of soluble guanylate cyclase | Bayer Pharma AG | 2015-03-25 | — | — | CN | disclosed |
| US-20140142069-A1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-22 | — | — | US | disclosed |
| EP-2493845-B1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | BAYER IP GMBH (DE) | 2013-12-25 | — | — | EP | disclosed |
| WO-2013174736-A1 | N-[3-(2-CARBOXYETHYL)PHENYL]PIPERIDIN-1-YLACETAMIDE DERIVATIVES AND USE THEREOF AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-11-28 | — | — | WO | disclosed |
| CN-102712577-A | Substituted 3-phenylpropionic acids and the use thereof | BAYER SCHERING PHARMA AG | 2012-10-03 | — | — | CN | disclosed |
| EP-2493845-A1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2012-09-05 | — | — | EP | disclosed |
| US-20110130445-A1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-02 | — | — | US | disclosed |
| US-20110130445-A1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-02 | — | — | US | disclosed |
| US-20110130445-A1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-02 | — | — | US | disclosed |
| WO-2011051165-A1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-05-05 | — | — | WO | disclosed |
| WO-2011051165-A1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152050-A1 | N-[3-(2-CARBOXYETHYL)PHENYL]PIPERIDIN-1-YLACETAMIDE DERIVATIVES AND USE THEREOF AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | GUCY1A2, GUCY1A1, GUCY1B2 | SMN1; SMN2 2261/4885TSHR 3063/4885CYP4F2 3531/4885 |
| US-20140142069-A1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | FABP3, PC, PAH | SMN1; SMN2 3173/4885TSHR 3882/4885CYP4F2 748/4885 |
| US-20110130445-A1 | SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF | FABP3, PC, PAH | SMN1; SMN2 3173/4885TSHR 3882/4885CYP4F2 748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.